AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03927391
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: enzalutamide treatment
Trial: NCT00133367
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously on day 2 before transplant.
Trial: NCT04164758
Drug: Pimavanserin
RxNorm normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
Trial: NCT04164758
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
Trial: NCT03298516
Drug: DCLL9718S
RxNorm normalized name: DCLL9718S
DrugBank: DCLL-9718S (DB17392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLL9718S will be administered as per the schedule specified in the respective arm.
Trial: NCT03298516
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine will be administered as per the schedule specified in the respective arm.
Trial: NCT01529554
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
Trial: NCT02092701
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04009876
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
Trial: NCT05561257
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin C
Trial: NCT04398134
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablet for oral administration
Trial: NCT02883439
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: local nasal application
Trial: NCT01386125
Drug: Mometasone Furoate Nasal Spray (MFNS)
RxNorm normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
Trial: NCT01866644
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bath transplanted liver with N-acetylcysteine
Trial: NCT01866644
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bath saline transplanted liver
Trial: NCT04085744
Drug: Lidocaine 10% Spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine will be apply on the cuff
Trial: NCT04085744
Drug: Mometasone nasal spray
RxNorm normalized name: mometasone Nasal Spray
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mometasone spray will be applied on the cuff
Trial: NCT01927588
Drug: Everolimus+Tacrolimus+Prednisone
RxNorm normalized name: Everolimus
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certican, introduced at Day7 post transplant + TACreduced + Steroids.
Trial: NCT01927588
Drug: Mycophenolate+Tacrolimus+Prednisone
RxNorm normalized name: mycophenolate
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myfortic + Tacrolimus full + Steroids, as control arm.
Trial: NCT01781234
Drug: Intranasal Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00721955
Drug: Inhaled loxapine 5 mg
RxNorm normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
Trial: NCT00721955
Drug: Inhaled loxapine 10 mg
RxNorm normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
Trial: NCT01353716
Drug: Dolutegravir 50 mg
RxNorm normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
Trial: NCT04496037
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: See NCT03994783
Trial: NCT01928615
Drug: Trastuzumab - intravenous solution
RxNorm normalized name: trastuzumab Injectable Solution
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
Trial: NCT01928615
Drug: Trastuzumab - subcutaneous solution
RxNorm normalized name: trastuzumab Injectable Solution
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab was supplied as a solution for subcutaneous injection.
Trial: NCT00222040
Drug: Levovist
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D-Galactose and palmitic palmitique intravenous 4 g
Trial: NCT00136656
Drug: antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cephalosporine by oral route : cefixime
Trial: NCT00515216
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00515216
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00142116
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
Trial: NCT00142116
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
Trial: NCT02459886
Drug: BIIB054
RxNorm normalized name: Immunoglobulin g1, anti-(human .alpha.-synuclein) (human monoclonal biib054 .gamma.1-chain), disulfide with human monoclonal biib054 .kappa.-chain, dimer
DrugBank: Cinpanemab (DB16127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT03281096
Drug: Berberine hydrochloride
RxNorm normalized name: Berberine Hydrochloride
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
Trial: NCT02928458
Drug: Omnipaque
RxNorm normalized name: Omnipaque 9
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02928458
Drug: MD-Gastroview
RxNorm normalized name: MD-Gastroview
DrugBank: Diatrizoate (DB00271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01450800
Drug: Nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
Trial: NCT02250651
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
Trial: NCT02250651
Drug: Active Comparator: Timolol 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
Trial: NCT02250651
Drug: Timolol Vehicle (placebo)
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
Trial: NCT00344045
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
Trial: NCT00875082
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast, chewing tablets 5mg, once daily, 8 weeks
Trial: NCT01896492
Drug: NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
Trial: NCT02798419
Drug: Active01 Cream
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04167462
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on Specified Days
Trial: NCT01830309
Drug: CJ-12420 200mg
RxNorm normalized name: ethanol
DrugBank: Tegoprazan (DB16690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition
Trial: NCT02767947
Drug: Luliconazole Cream 1%
DrugBank: Luliconazole (DB08933)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Luliconazole cream will be applied per schedule specified in the arm.
Trial: NCT03432273
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine mint lozenge, 2 mg
Trial: NCT03432273
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NiQuitin mint lozenge, 2 mg
Trial: NCT01487629
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab, 1.5 mg, intravitreal, throughout the study
Trial: NCT01487629
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab, 0.5 mg, intravitreal, throughout the study
Trial: NCT01041235
Drug: ATI-1123 (active drug = docetaxel)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
Trial: NCT00756717
Drug: MK-0752
RxNorm normalized name: MK-0752
DrugBank: MK-0752 (DB12852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
Trial: NCT02262559
Drug: BIBR 277 tablet
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02262559
Drug: BIBR 277 capsule
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04220775
Drug: Bintrafusp Alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01720849
Drug: Fampyra
RxNorm normalized name: Ampyra
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The will be given as per normal patient treatment plan
Trial: NCT03077009
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided injection for plantaris friction syndrome
Trial: NCT02846233
Drug: basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participant will continue with the basal insulin.
Trial: NCT02846233
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empagliflozin will be added to a basal insulin.
Trial: NCT02846233
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The participant will continue with metformin.
Trial: NCT01318161
Drug: Ropivacaine + opioid epidurally
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with local anesthetic + opioid
Trial: NCT01318161
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine via PCA pump
Trial: NCT00047047
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00047047
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00047047
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02418754
Drug: REGN2176-3
RxNorm normalized name: Immunoglobulin g4, anti-(human platelet-derived growth factor receptor~) (human monoclonal regn2176 heavy chain), disulfide with human monoclonal regn2176 k-chain, dimer
DrugBank: Rinucumab (DB16313)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02418754
Drug: Intravitreal Aflibercept Injection (IAI)
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03853369
Drug: Nifekalant hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Nifekalant (DB16008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
Trial: NCT01327521
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT00559741
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02518607
Drug: MGB-BP-3
RxNorm normalized name: MGB-BP-3
DrugBank: MGB-BP-3 (DB12892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of CDI
Trial: NCT00250705
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
Trial: NCT03602027
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
Trial: NCT03602027
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib 250mg orally daily for three weeks
Trial: NCT01327521
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care
Trial: NCT01327521
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT01327521
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care
Trial: NCT01327521
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT03111381
Drug: Toradol
RxNorm normalized name: Toradol
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV toradol
Trial: NCT04502849
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg Vitamin E per os 1 per day (1 month).
Trial: NCT00597428
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mcg capsules twice daily (BID)
Trial: NCT02203578
Drug: romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00777855
Drug: warfarin plus rifampin
RxNorm normalized name: Rifampin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: warfarin 7.5mg po x 1; rifampin 600mg IV x 1
Trial: NCT00777855
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: warfarin 7.5mg po x 1
Trial: NCT00411333
Drug: triamcinolone acetonide (Kenalog)
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03785691
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Trial: NCT03785691
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Trial: NCT02508064
Drug: BMS-663068
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-663068
Trial: NCT00003969
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02269735
Drug: Dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
Trial: NCT00378027
Drug: Fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer Fondaparinux Risk Stratify
Trial: NCT01451996
Drug: Claritin
RxNorm normalized name: Claritin
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will be given 10mg Claritin tablet.
Trial: NCT04202458
Drug: intra-arterial tenecteplase administration
RxNorm normalized name: methotrexate
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
Trial: NCT00243152
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: : 25mg and 50mg tablets
Trial: NCT01149824
Drug: Salvinorin A
RxNorm normalized name: Salvinorin A
DrugBank: Salvinorin A (DB12327)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00099957
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00668096
Drug: Levitra (Vardenafil, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
Trial: NCT01543867
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescribed at the discretion of the treating physician according to product labelling